CoronaVac is an inactivated SARS-CoV-2 vaccine approved for use in 48 countries. In collaboration with the Ministry of Health in Dominican Republic, we tested whether CoronaVac (2x) + Pfizer booster induces neutralizing Abs to Delta and Omicron. (1/)
We analyzed plasma samples from 101 participants in Dominican Republic (DR) who received the BNT162b2 booster >4 weeks after the 2x of CoronaVac. We compared them to samples from people at Yale who received 2x of BNT162b2.
⬆️ ⬆️ Ab induced by heterologous prime & boost.(2/)
Next, @carolilucas & @ValterVSM analyzed NAb against ancestral vs. Delta variant. CoronaVac 2x followed by Pfizer mRNA vax booster robustly elevated NAb against both virus types, level similar to 2x Pfizer vaccine. (3/)
Just focusing on Pfizer 2x, omicron had the highest escape from neutralization compared to other VOCs (using authentic virus isolates), reducing the NAb PRNT50 levels by 11.9x compared to ancestral virus. Similar data have already been reported by others. (4/)
In CoronaVac fully vaccinated (2x) people, there was NO detectable neutralization against the infectious Omicron virus. Antibodies were assayed at mean days from second Coronavac shot of 113 days (with SD 33 days). (5/)
However, after the Pfizer mRNA booster, CoronaVac recipients elicited detectable levels of neutralization against omicron. Note that PRNT50 is reduced by 7.3x against Omicron compared to the ancestral virus. (6/)
How does prior infection modify neutralization against Omicron? In the mRNA vaccine recipients (28 days after second dose), prior infection provided advantages in cross protection against VOCs, including Omicron. (7/)
Unfortunately, in the CoronaVac 2x recipients boosted with Pfizer mRNA vax, prior infection made no difference to the neutralization capacity against Omicron. (8/)
Immunologically, this difference is interesting. Prior infection only synergies with the mRNA vax to elevate broadly neutralizing Ab but not with inactivated vax. This may relate to the persistent GC responses in mRNA vax reported by @TheBcellArtist. (9/) nature.com/articles/s4158…
In terms of public health, CoronaVac 2x is insufficient to neutralize Omicron. Even with CoronaVac 2x plus Pfizer booster, NAb is only 1.4x higher than 2x mRNA alone. Thus, CoronaVac recipients may need 2 additional booster doses to reach levels needed against Omicron. (10/)
Lots of amazing folks from Dominican Republic and Yale contributed to this work. Special thank you to @SVermund for orchestrating this collaboration, and Drs. Eddy Perez-Then and Marija Miric for their leadership in DR. Always fantastic @carolilucas@ValterVSM 👏🏼 👏🏼 (end)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
This thread is about our new preprint on transposable element called long interspersed nuclear elements (LINE-1/L1). When expressed excessively in the cerebellum, L1 causes ataxia (impaired coordination).
Human genome is occupied in large part by transposable elements or jumping genes. LINE-1 occupies ~20% of our genome, compared to only 1.1% by exons. Some evolutionarily young LINE-1 are still active and are a rare cause of genetic diseases. (2/)
In addition, L1 may even promote the process of aging & age-related diseases in humans. Until recently, research focused on their activity in the germline. Now, their activity in somatic tissues during a lifespan is being studied. Fascinating review👇🏽(3/) nature.com/articles/s4158…
Our new study by @JieunOh9@ericsongg@MiyuMoriyama et al shows that immune priming via intranasal route provides superior protection against heterologous respiratory virus challenge. The key is in inducing local secretory IgA with broader coverage. (1/)
Mucosal surface epithelium expresses polymeric Ig receptor (pIgR), which transports dimeric IgA + J-chain secreted from plasma cells within the tissue, across to the luminal side. IgA dimer + J-Chain + part of pIgR is released as ‘secretory IgA’. Figure by @BioRender. (2/)
The secretory IgA can bind viruses, bacteria, toxin in the lumen of intestine and neutralize them. Advantages of secretory IgA is the extended longevity as well as having 4 Fab instead of 2 Fab (monomeric IgA) to bind to the antigen. Secretory IgA is well studied in the gut. (3/)
Despite a number of studies, whether HIV infected individuals are at higher risk of COVID-19 diagnosis, hospitalization, and mortality remains unclear due to variable results found in the population studies, cohort studies, and case series. (2/)
People with chronic HIV infection have distinct immune profiles, such as reduced IFN-I, chronic inflammation, CD4 ⬇️, CD8 exhaustion, poor B cell responses, which impair immune defense against SARS-CoV-2. (Beautiful figure 🎨 by @YYexin) (3/)
A preprint by Michael Simon et al @ArcadiaHealthIT shows that COVID vaccines given before or AFTER infection can reduce incidence of #longCOVID, based on a retrospective analysis of the health record of 240,648 COVID-19-infected people. 🧵(1/)
People who received at least one dose of any of the 3 COVID vaccines in the US prior to COVID diagnosis were 8.8x less likely to report >1 long COVID symptoms between 12-20 weeks after diagnosis. (2/)
This reduction in LC risk appears high, given other studies that found 50% reduction or no reduction by prior vaccination in LC among breakthrough infection. Perhaps this depends on how one measures and defines long covid. (3/)
Our latest study is about an immunocompromised patient with persistent COVID ➡️ treated with remdesivir but developed resistant mutation ➡️ was then cured by monoclonal Ab cocktail. Study by @gandhisk@sneakyvirus1@epidememeology@marioph13 et al. (1/)
This patient received a course of rituximab (B cell depleting Ab) and bendamustine (chemo agent) for the treatment of Stage IV Non-Hodgkin's lymphoma. As a result, patient had extremely low number of T cells and low lymphocyte counts overall. Analysis by @peowenlu (2/)
So when she was infected with SARS-CoV-2, she was unable to clear the virus for over 150 days. She developed persistent fever, anosmia and ground glass opacities in her lungs. Her viral load stayed high until the remdesivir treatment. (3/)
For description of this study, please see my thread from when we first posted the paper in @medrxivpreprint in March 👇🏽 One of the deepest immune profiling that captures reinfection in a longitudinal manner. (2/)
In a nutshell, this transplant patient had, prior to reinfection;
• Huge levels of circulating innate and adaptive cytokines (chronic inflammation)
• Very few naive lymphocytes & dominant exhausted T cells
• Elicited poor and transient neutralizing Ab responses
(3/)